Company: BSX
Filing Date: 2025-02-24
Form Type: 424B2
Source: 0001104659-25-016521
Chunk: 10

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-02-24
Form: 424B2
Chunk 10
---
 American Medical Systems Europe B.V.
American Medical Systems Europe B.V. was incorporated on January 30, 2003 as a private company with limited liability ( besloten vennootschap met beperkte aansprakelijkheid ), under the laws of the Netherlands. Its registered office is located at Vestastraat 6, 6468 EX Kerkrade, The Netherlands. AMS Europe is registered with the Trade Register of the Chamber of Commerce in the Netherlands under number 34185686, is an indirect wholly-owned finance subsidiary of Boston Scientific. AMS Europe’s telephone number is +31-455467700.

<div align='center'>S-1</div>

TABLE OF CONTENTS

#### The Offering
The following summary contains basic information about the notes and is not intended to be complete. It does not contain all of the information that may be important to you. For a more detailed description of the notes, please refer to the section entitled “Description of the Notes” in this prospectus supplement and the section entitled “Description of Debt Securities” in the accompanying prospectus.

#### Issuer
American Medical Systems Europe B.V., a Dutch private company with limited liability ( besloten vennootschap met beperkte aansprakelijkheid ). The Issuer is an indirect wholly-owned finance subsidiary of Boston Scientific.

#### Issuer Legal Entity Identifier
549300AA2JE6ZQ5D2493.

#### Guarantor
Boston Scientific Corporation, a Delaware corporation.

#### Notes Offered
€850,000,000 aggregate principal amount of 3.000% senior notes due 2031.

€650,000,000 aggregate principal amount of 3.250% senior notes due 2034.

#### Maturity Date
March 8, 2031 for the 2031 Notes.

March 8, 2034 for the 2034 Notes.

#### Interest Payment Dates
Interest will be paid annually in arrears on March 8 of each year, commencing March 8, 2026.

#### Original Issue Discount
We intend to treat the notes of each series as being issued with original issue discount (“OID”) for U.S. federal income tax purposes. See “Material U.S. Federal Income Tax Consequences — U.S. Federal Income Taxation of U.S. Holders — Original Issue Discount” in this prospectus supplement.

#### Use of Proceeds
We intend to use the net proceeds from this offering, together with cash on hand